Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 2 |
| Emerging Pharmaceutical Market: Argentina - Introduction | 11 | 1 |
| Overview | 11 | 1 |
| Emerging Pharmaceutical Market: Argentina - Industry Characterstics | 12 | 23 |
| Market Size and Forecast | 12 | 1 |
| Overview | 12 | 1 |
| Revenue Forecast | 12 | 1 |
| Prescription vs. OTC Drugs | 13 | 1 |
| Revenue Analysis by Therapy Area | 14 | 1 |
| Competitive Landscape | 15 | 1 |
| Overview | 15 | 1 |
| Market Share - Domestic vs. Foreign | 16 | 1 |
| Market Share Analysis | 17 | 1 |
| Top 10 Pharmaceutical Companies - Prescription Drugs Market | 17 | 1 |
| Major Domestic Players | 18 | 1 |
| Laboratorios Roemmers | 18 | 1 |
| Bago Group/Laboratorios Bago | 19 | 1 |
| Gador S.A. | 19 | 1 |
| Major Foreign Players | 20 | 1 |
| Bayer Healthcare AG | 20 | 1 |
| Ivax Corporation (Ivax Argentina) | 20 | 1 |
| Pfizer, Inc. | 21 | 1 |
| GlaxoSmithKline Plc. | 21 | 1 |
| Sanofi | 22 | 1 |
| Novartis | 22 | 2 |
| Pharmaceutical Trade - Forecast | 24 | 1 |
| Pharmaceutical Exports, Imports and Balance of Trade | 24 | 2 |
| Exports by Destination | 26 | 1 |
| Imports by Source | 27 | 1 |
| Pharmaceutical Marketing and Distribution | 28 | 1 |
| Pharmaceutical Distribution System | 28 | 1 |
| Major Distributors | 29 | 1 |
| Disprofarma | 29 | 1 |
| Farmanet | 29 | 1 |
| Rofina | 29 | 1 |
| Clinical Trials | 30 | 1 |
| Number of Clinical Trials Registered in Argentina | 30 | 1 |
| Number of Clinical Trials Registered in Argentina - Trend Analysis | 31 | 1 |
| Number of Registered Clinical Trial Sites per Million Population | 32 | 1 |
| Healthcare System in Argentina | 33 | 1 |
| Public Healthcare | 33 | 1 |
| Private Healthcare | 34 | 1 |
| PESTL Analysis | 34 | 1 |
| Emerging Pharmaceutical Market: Argentina - Macroeconomic Environment | 35 | 19 |
| Demographic Analysis | 35 | 1 |
| Population Size, Growth, and Structure | 35 | 1 |
| Patient Availability for Major Diseases | 36 | 1 |
| Mortality and Major Causes of Deaths | 37 | 1 |
| Forecasts of Major Diseases | 38 | 1 |
| HIV/AIDS | 38 | 1 |
| Cardiovascular Diseases | 39 | 1 |
| Diabetes | 40 | 1 |
| Cancer | 41 | 1 |
| Chronic Obstructive Pulmonary Diseases (COPD) and Asthma | 42 | 1 |
| National/Domestic Income | 43 | 1 |
| Annual GDP Growth Rate - Comparative Analysis | 43 | 1 |
| Gross National Income (GNI) per Capita in Argentina | 44 | 1 |
| Expenditure on Health | 45 | 1 |
| Total Healthcare Expenditure - Trend Analysis | 46 | 1 |
| Total Healthcare Expenditure as Percentage of GDP | 46 | 1 |
| Total Healthcare Expenditure per Capita | 47 | 1 |
| Healthcare Expenditure - Comparative Analysis | 48 | 1 |
| Healthcare Expenditure Ratios | 48 | 1 |
| Per Capita Expenditure on Health | 49 | 1 |
| Healthcare Workforce and Infrastructure | 50 | 1 |
| Healthcare Workforce | 50 | 1 |
| Number of Health Care Professionals and Their Density per 10,000 Population | 50 | 2 |
| Growth in the Number of Principal Investigators | 52 | 1 |
| Healthcare Infrastructure | 53 | 1 |
| Healthcare Infrastructure - Density per 10,000 Population | 53 | 1 |
| Number of Hospitals by Provinces | 53 | 1 |
| Emerging Pharmaceutical Market: Argentina - Healthcare Regulation | 54 | 8 |
| Pharmaceutical Regulation in Argentina | 54 | 1 |
| National Healthcare Policy Framework in Argentina | 54 | 1 |
| Intellectual Property Laws and Medicines | 54 | 1 |
| Generics Law | 55 | 1 |
| Legal Provisions | 55 | 1 |
| Overview | 55 | 1 |
| Clinical Trials | 56 | 1 |
| Marketing Authorization | 56 | 1 |
| Regulatory Inspection | 56 | 1 |
| Licensing | 56 | 1 |
| Market and Quality Control | 57 | 1 |
| Promotion and Advertising of Medicines /Drugs | 57 | 1 |
| Import Control | 57 | 1 |
| Pharmacovigilance | 57 | 1 |
| Clinical Trial and Drug Approval Process | 58 | 1 |
| Approval Process for Clinical Trials in Argentina | 58 | 1 |
| Registration of Drugs | 59 | 1 |
| Pricing and Regulation | 60 | 1 |
| Cost of Medical Treatment | 60 | 1 |
| Pricing of Medicines | 61 | 1 |
| Emerging Pharmaceutical Market: Argentina - Strategic Consolidations | 62 | 19 |
| Overview | 62 | 1 |
| Mergers and Acquisitions | 63 | 1 |
| Deals by Year | 63 | 1 |
| Deal by Value | 64 | 1 |
| Top 10 M&A Deals | 65 | 1 |
| Pfizer Acquires Rights of Exubera from Sanofi | 66 | 1 |
| 3M Sells Pharmaceuticals Business to Graceway | 66 | 1 |
| Meda Acquires Commercialization Rights of Sublinox and OX-NLA from Orexo | 66 | 1 |
| Royalty Pharma Acquires Lyrica Royalty Interest from Northwestern University | 66 | 1 |
| GlaxoSmithKline Acquires Pharmaceutical Brands from UCB | 66 | 1 |
| Royalty Pharma Acquires Remicade Royalty Interest from New York University | 66 | 1 |
| Prosidion Completes Sale of Dipeptidyl Peptidase IV Patent Estate and Associated Royalty Interest to Royalty Pharma | 67 | 1 |
| GlaxoSmithKline Acquires Arixtra and Fraxiparine from Sanofi | 67 | 1 |
| Meda Completes Acquisition of Global Rights to Elidel from Novartis | 67 | 1 |
| Aspen Pharmacare Acquires Healthcare Products from GlaxoSmithKline | 67 | 1 |
| Licensing Agreements | 68 | 1 |
| Licensing Agreements by Year | 68 | 1 |
| Deals by Value | 69 | 1 |
| Top 10 Licensing Deals | 70 | 1 |
| GlaxoSmithKline Enters into an Agreement with Actelion | 71 | 1 |
| Isis Pharmaceuticals Enters into Licensing Agreement with Genzyme | 71 | 1 |
| Cephalon Enters into Licensing Agreement with Mesoblast | 71 | 1 |
| f-star Biotechnologische Enters into Licensing Agreement with Boehringer Ingelheim | 72 | 1 |
| Galapagos Enters into Licensing Agreement with Eli Lilly and Company | 72 | 1 |
| Vertex Pharmaceuticals Enters into Licensing Agreement with Alios BioPharma | 72 | 1 |
| Nektar Therapeutics Enters into Licensing Agreement with AstraZeneca | 73 | 1 |
| Incyte Enters into Collaboration and License Agreement with Novartis | 73 | 1 |
| AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals | 74 | 1 |
| AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept | 74 | 1 |
| Co-Development Deals | 75 | 1 |
| Deals by Year | 75 | 1 |
| Deals by Value | 76 | 1 |
| Top 10 Co-Development Deals | 77 | 1 |
| Eli Lilly Enters into Co-Development Agreement with Boehringer Ingelheim | 78 | 1 |
| Boehringer Ingelheim Enters into Co-Development Agreement with MacroGenic | 78 | 1 |
| GlaxoSmithKline Enters into Co-Development Agreement with Genmab | 78 | 1 |
| GlaxoSmithKline Enters into Co-Development Agreement with ChemoCentryx | 78 | 1 |
| GlaxoSmithKline Enters into Agreement with Archemix | 79 | 1 |
| GlaxoSmithKline Signs an Agreement with OncoMed Pharmaceuticals | 79 | 1 |
| GlaxoSmithKline Enters Into an Agreement with EPIX Pharmaceuticals | 79 | 1 |
| GlaxoSmithKline Enters into Collaboration with Synta Pharmaceuticals | 79 | 1 |
| Bristol-Myers Enters into Co-Development Agreement with Pfizer | 80 | 1 |
| Celgene Enters into Co-Development Agreement with Acceleron Pharma | 80 | 1 |
| Emerging Pharmaceutical Market: Argentina - Contract Research Organizations (CRO) Landscape | 81 | 14 |
| Contract Research Organization (CRO) Sector in Argentina | 81 | 1 |
| Clinical Trial Market Size and Growth | 81 | 1 |
| CRO Profiles | 82 | 1 |
| Abel Santos &Asociados | 82 | 1 |
| Business Description | 83 | 1 |
| Activa CRO | 83 | 1 |
| Business Description | 83 | 1 |
| Blanchard &Asociados | 84 | 1 |
| Business Description | 84 | 1 |
| EGCP | 85 | 1 |
| Business Description | 85 | 1 |
| Klixar | 86 | 1 |
| Business Description | 86 | 1 |
| LatinClin | 87 | 1 |
| Business Description | 87 | 1 |
| MMatiss | 88 | 1 |
| Business Description | 88 | 1 |
| ECLA | 89 | 1 |
| Business Description | 89 | 1 |
| Quintiles | 90 | 1 |
| Business Description | 90 | 1 |
| Covance | 91 | 1 |
| Business Description | 91 | 1 |
| Charles River | 92 | 1 |
| Business Description | 92 | 1 |
| INC Research | 93 | 1 |
| Business Description | 93 | 1 |
| Theorem Clinical Research | 94 | 1 |
| Business Description | 94 | 1 |
| Emerging Pharmaceutical Market: Argentina - Appendix | 95 | 4 |
| Market Definitions | 95 | 1 |
| Abbreviations | 95 | 2 |
| Research Methodology | 97 | 1 |
| Industry Characteristics | 97 | 1 |
| Macroeconomic Environment | 97 | 1 |
| Healthcare Regulations | 97 | 1 |
| Strategic Consolidations | 97 | 1 |
| CRO Landscape | 97 | 1 |
| Contact Us | 98 | 1 |
| Disclaimer | 98 | 1 |
| Sources | 98 | 1 |